Juan J. Pérez Villar, PhD.
Chief Executive Officer.

Holds a degree in Biochemistry and a Ph.D. in Immunology and Inflammation by the Autonoma University of Madrid (UAM). Juan developed an extensive international career in the biopharmaceutical industry in drug discovery and business development. Previously, he was the business development partner at the biopharmaceutical specialized consultancy company, Biolty (Madrid, Spain), Director of the industrial affairs department at the CEU-Cardenal Herrera University (Valencia, Spain); group head oncology at Agensys / Astellas Inc. (Santa Monica , CA , USA ) and Bristol-Myers Squibb Co. (Princeton, NJ , USA). Juan participated in pre-clinical development of biologics abatacept/Orencia® and belatacept/Nulojix® modulators of the CD28 co-stimulatory activity for inflammation and transplantation; fully human monoclonal antibody AGS-PSCA for advanced pancreatic cancer and the small molecule dasatinib (SprycelTM), a multiple tyrosine kinase inhibitor for chronic myeloid leukemia; additionally, he is inventor of numerous patents granted in USA and Europe and peer reviewed publications. Previously, he participated during the fund raising activities of a venture capital fund and the launching of a vaccine specialized company.

Senior Scientific Team:

Marta Compte Grau, MD, PhD.
Director R&D.

Marta attended Medical School at Navarra University (Pamplona, Spain) and her residency in Immunology at the Hospital Universitario Puerta de Hierro (Madrid); shortly after, she obtained a fellowship to attend the Molecular Medicine Program at the Mayo Clinic (Rochester, MN, USA). Further, she earned a PhD in Immunology from the Autónoma University of Madrid. Marta has extensive experience in antibody engineering and development of gene and cellular immunotherapeutic strategies against cancer based on recombinant bispecific antibodies. Marta has published over 30 peer reviewed research articles and book chapters and contributed to the Trimerbody technology development.

Latest News

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...

LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis...

Leadartis to present at BioSpain 2016 in Bilbao

Leadartis will participate in BioSpain 2016 to be held...